When compared to monotherapy with VEGF siRNA and GMP, the (GMP ​+ ​VEGF)-LCP-AA reduced VEGF mRNA expression levels in cancer cells, inhibited tumor vasculature formation, and induced cancer cell apoptosis by a large margin with fewer side effects in H460 tumor cells (Zhang et al., 2013). This evidence concerns the gene VEGFA and neoplasm.